On August 11, 2026, the Centers for Medicare & Medicaid Services (CMS) published an operative procedural notice with comment period in the Federal Register establishing the Regulatory Alignment for Predictable and Immediate Device Coverage (RAPID) pathway (FR Doc. 2026-16368; 91 FR 51710–51718; File Code CMS-3487-NC; Docket CMS-2026-2674). Building upon the initial joint FDA-CMS interagency announcement from April 23, 2026, this procedural notice establishes the formal eligibility boundaries, evidence requirements, and National Coverage Determination (NCD) timelines for the new program, with public comments open through October 13, 2026.
For medical device manufacturers, regulatory affairs executives, health policy strategists, and Medicare reimbursement specialists, the publication of the RAPID notice creates immediate clarity around a critical market access question:
Does the CMS-FDA RAPID pathway provide a 60-day Medicare national coverage guarantee for newly authorized Breakthrough devices, can manufacturers with ongoing clinical trials enroll, and what does this mean for technologies—such as last week's Abbott Libre Duo De Novo—that have already received FDA clearance?
The direct operational answers define the strict boundaries of CMS coverage policy:
- RAPID is an investigational-stage pathway, not post-market coverage: RAPID is a prospective, voluntary NCD mechanism open strictly to technologies at the Investigational Device Exemption (IDE) presubmission stage. It requires CMS and FDA parallel review during clinical trial design, before pivotal study execution.
- Already-authorized devices are excluded: Technologies that have already obtained FDA clearance, De Novo classification, or Premarket Approval (PMA)—including the Abbott Libre Duo 10 Day Continuous Glucose-Ketone Monitoring System authorized on August 25, 2026—are categorically ineligible for RAPID. CMS directs post-market sponsors to standard coverage mechanisms under 78 FR 48164, local Medicare Administrative Contractor (MAC) coverage, or claim-by-claim adjudication.
- In Vitro Diagnostics (IVDs) will not be accepted: CMS explicitly excludes IVDs and diagnostic laboratory tests from RAPID, determining that most Breakthrough IVD coverage should remain with Medicare Administrative Contractors through existing local pathways.
- The TCET pathway is paused for new applicants: With the introduction of RAPID, CMS paused the Transitional Coverage for Emerging Technologies (TCET) pathway for new candidates. The August 11 notice does not publish a separate processing rule for any manufacturer already in the TCET queue. TCET itself was established in the August 12, 2024 final notice (89 FR 65724).
- Same-day proposed NCD is an operational goal for completers, not an automatic guarantee: For devices that successfully complete RAPID parallel review, CMS will post a tracking sheet and Proposed NCD on the exact same day FDA grants market authorization, aiming for a Final NCD within 60 days (Class II De Novo) or 90 days (Class III PMA).
- Legally binding comment deadline is October 13, 2026: While early legal summaries paraphrased a 60-day calendar count landing on October 10, the official Federal Register deadline for public comments on CMS-3487-NC is October 13, 2026.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ CMS RAPID COVERAGE PATHWAY REGULATORY SCORECARD │
├──────────────────────────┬───────────────────────────────────────────────────────────────────────┤
│ Dimension / Metric │ Documented Status / Operational Specification │
├──────────────────────────┼───────────────────────────────────────────────────────────────────────┤
│ Operative Notice │ Federal Register 91 FR 51710–51718; FR Doc. 2026-16368; CMS-3487-NC │
│ Publication Date │ August 11, 2026 (Follows April 23, 2026 CMS-FDA joint announcement) │
│ Public Comment Deadline │ October 13, 2026 (Binding Federal Register date; docket CMS-2026-2674)│
│ Core Statutory Authority │ Social Security Act § 1862(a)(1)(A) (Reasonable & Necessary Standard) │
│ Eligible Device Class II │ Presumptive Class II Breakthrough Devices participating in FDA TAP │
│ │ and planning to submit a De Novo classification request │
│ Eligible Device Class III│ Class III Breakthrough Devices planning a PMA (TAP encouraged) │
│ Entry Timing Gate │ STRICTLY IDE PRESUBMISSION (Prior to pivotal study initiation) │
│ Ineligible Technologies │ 1. Already market-authorized devices (e.g. Libre Duo De Novo) │
│ │ 2. Devices with IDE trials already underway │
│ │ 3. In Vitro Diagnostics (IVDs) & diagnostic laboratory tests │
│ TCET Program Status │ PAUSED for new candidates as CMS shifts operational focus to RAPID │
│ Accelerated NCD Timeline │ Proposed NCD posted on Day of FDA Authorization; Final NCD goal ~60d │
│ │ for Class II De Novo / ~90d for Class III PMA (Completers Only) │
└──────────────────────────┴───────────────────────────────────────────────────────────────────────┘
What Document Actually Opened RAPID, and Why the Comment Deadline Is October 13
Understanding the legal standing of the RAPID pathway requires distinguishing between high-level interagency announcements and legally operative procedural rulemaking:
The Rulemaking Sequence: April 23 Announcement vs. August 11 Notice
- The April 23, 2026 Press Announcement: CMS and the FDA issued a joint press release outlining the conceptual framework of the RAPID pathway. This initial announcement generated widespread industry enthusiasm by describing a coordinated model where Medicare coverage could take effect within 60 days of FDA authorization. However, the April announcement did not establish formal application procedures or binding eligibility criteria.
- The August 11, 2026 Federal Register Notice (CMS-3487-NC): The legally binding architecture was established via Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway, published at 91 FR 51710. This notice formally defines the entry gates, evidentiary expectations, and administrative coordination mechanisms.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ RAPID PATHWAY LEGISLATIVE & REGULATORY TIMELINE │
├───────────────────────┬───────────────────────────────┬──────────────────────────────────────────┤
│ Milestone Date │ Regulatory Event / Publication│ Practical Impact on Device Access │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ April 23, 2026 │ Joint CMS-FDA Press Release │ Announced high-level intent to coordinate│
│ │ "RAPID Coverage Pathway" │ Breakthrough device coverage timelines. │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ August 11, 2026 │ Federal Register 91 FR 51710 │ Operative procedural notice published; │
│ │ (Doc. 2026-16368; CMS-3487-NC)│ TCET paused; IDE gates established. │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ October 13, 2026 │ Public Comment Period Closes │ Binding Federal Register comment deadline│
│ │ (Docket CMS-2026-2674) │ for stakeholders on RAPID architecture. │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ After comments │ Subsequent final notice │ CMS says it will respond to comments in │
│ │ │ a later final notice; no enrollment year │
│ │ │ is specified in the August 11 document. │
└───────────────────────┴───────────────────────────────┴──────────────────────────────────────────┘
Resolving the Comment Deadline Discrepancy
A point of confusion across early trade analyses and legal advisories involves the exact public comment deadline:
- Certain law-firm publications (including Holland & Knight's August 2026 brief) cited an October 10, 2026 deadline based on a 60-day count from the August 11 publication date.
- The official Federal Register DATES line is October 13, 2026. Device trade associations and manufacturers submitting formal feedback must use that date in docket
CMS-2026-2674.
Which Devices Are Eligible, and Why Are Authorized Products and IVDs Out?
CMS structured the RAPID pathway around strict statutory and operational filters designed to maximize the likelihood that clinical evidence generated during premarket trials will satisfy Medicare's "reasonable and necessary" standard under Section 1862(a)(1)(A) of the Social Security Act.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ CMS RAPID PATHWAY ELIGIBILITY & EXCLUSION MATRIX │
├───────────────────────────────────────┬─────────────────────────────┬────────────────────────────┤
│ Device Category / Developmental Stage │ RAPID Pathway Status │ Governing Policy / Reason │
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ Presumptive Class II Breakthrough + │ ELIGIBLE │ Primary target track for │
│ Enrolled in TAP + Planning De Novo │ (IDE Presubmission Stage) │ expedited Class II NCD. │
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ Class III Breakthrough Device + │ ELIGIBLE │ Class III target track; TAP│
│ Planning PMA Application │ (IDE Presubmission Stage) │ encouraged but not mandatory│
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ Breakthrough Devices with IDE Study │ INELIGIBLE │ Clinical trial protocol │
│ Already Active / Enrolling │ (Redirected to standard NCD)│ locked; cannot align CMS. │
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ Market-Authorized Breakthrough Tech │ INELIGIBLE │ Past IDE phase; must use │
│ (Cleared, De Novo, or PMA Approved) │ (Redirected to standard NCD)│ standard NCD/LCD channels. │
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ In Vitro Diagnostics (IVDs) and │ INELIGIBLE │ Excluded by policy; MAC / │
│ Diagnostic Laboratory Tests │ (Redirected to MACs/MolDX) │ LCD local review preferred.│
├───────────────────────────────────────┼─────────────────────────────┼────────────────────────────┤
│ Non-Breakthrough Medical Devices │ INELIGIBLE │ Statutory designation is │
│ (Standard 510(k) or 510(k)-exempt) │ (Standard coverage tracks) │ an absolute prerequisite. │
└───────────────────────────────────────┴─────────────────────────────┴────────────────────────────┘
The Three Mandatory Eligibility Gates
To qualify for RAPID review, a medical technology must satisfy three cumulative criteria:
- Breakthrough Device Designation: The technology must have received formal designation under Section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
- Program Track Alignment:
- For Class II candidates: The sponsor must be actively enrolled in the FDA Center for Devices and Radiological Health (CDRH) Total Product Life Cycle Advisory Program (TAP) and intend to seek market access via a De Novo classification request.
- For Class III candidates: The sponsor must be preparing a Premarket Approval (PMA) application. (TAP participation is encouraged for Class III products but not strictly mandatory).
- IDE Presubmission Stage Entry: The manufacturer must submit its RAPID application while the technology is still in the IDE presubmission phase, before clinical protocol finalization and before study enrollment begins.
The FR also requires that the device not already be the subject of a controlling Medicare NCD, that available information not immediately show the device falls outside a Medicare benefit category, and that the device not otherwise be excluded from coverage by statute or 42 CFR part 411, subpart A. A footnote to the Class II De Novo bullet also includes certain 510(k) devices whose primary predicate was authorized via De Novo no earlier than 18 months before RAPID acceptance.
Why Already-Authorized Devices Are Excluded
The central premise of RAPID is pre-trial evidence alignment. Under traditional regulatory workflows, device developers design pivotal clinical trials solely to meet FDA standards of "safety and effectiveness." However, FDA clearance standards frequently differ from Medicare's statutory coverage standard, which requires proof of "reasonable and necessary" clinical benefit specifically in Medicare-aged beneficiaries (adults 65 and older or disabled individuals).
Once a device has completed its clinical trials and received FDA clearance or De Novo authorization, the opportunity for CMS coverage staff to co-design clinical trial endpoints, sample sizes, and geriatric sub-analyses has passed. For devices already on the market, CMS cannot apply RAPID's parallel evidence model and therefore directs sponsors to standard National Coverage Determination requests (78 FR 48164) or MAC-level coverage determinations.
Why In Vitro Diagnostics (IVDs) Are Excluded
The procedural notice explicitly bars IVDs, including companion diagnostics and clinical laboratory tests, from entering RAPID. CMS's stated reason is operational, not a safety ranking: in vitro diagnostic technologies are a highly specific coverage area that CMS has historically delegated to specialized Medicare Administrative Contractors, and CMS believes most Breakthrough IVD coverage determinations should remain with MACs. In the rare case where manufacturers and CMS agree that an NCD is appropriate for an IVD, the notice points those sponsors to an ordinary NCD request under 78 FR 48164. Specialized MAC programs such as MolDX may still be relevant for individual tests; that is MAC practice, not a RAPID eligibility rule.
What Happens to TCET for New Candidates After August 11, 2026?
A transformative policy shift embedded within the August 11 notice is the formal suspension of the Transitional Coverage for Emerging Technologies (TCET) pathway.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ CMS COVERAGE PATHWAY COMPARISON: RAPID VS. TCET │
├───────────────────────┬───────────────────────────────────┬──────────────────────────────────────┤
│ Program Dimension │ RAPID Pathway (CMS-3487-NC) │ TCET Pathway (Aug. 12, 2024 Notice) │
├───────────────────────┼───────────────────────────────────┼──────────────────────────────────────┤
│ Current Status │ ACTIVE / Open for Public Comment │ PAUSED for new candidate submissions │
│ Program Timing Gate │ IDE Presubmission Stage (Pre-Trial)│ Pre-market engagement under the │
│ │ │ August 12, 2024 TCET notice │
│ Evidence Mechanism │ Parallel trial design (CMS + FDA) │ Evidence Preview / Post-market CED │
│ FDA TAP Requirement │ Mandatory for Class II De Novo │ Encouraged, but not mandatory │
│ NCD Action at Launch │ Proposed NCD on FDA Approval Day │ Proposed NCD within ~6 months post-AP│
│ Target Final NCD Goal │ ~60 days (Class II) / ~90d (Cl III│ ~12 months following FDA clearance │
│ Coverage Model │ Upfront NCD; CED only if required │ Predominantly Coverage with Evidence │
│ │ for high-risk residual questions │ Development (CED) transitional model │
└───────────────────────┴───────────────────────────────────┴──────────────────────────────────────┘
The Transition from TCET to RAPID
Finalized on August 12, 2024 (89 FR 65724), the TCET pathway was originally designed to bridge the gap between FDA authorization and Medicare payment by offering transitional coverage coupled with post-market Coverage with Evidence Development (CED). TCET engaged manufacturers later in the product lifecycle than RAPID's IDE-presubmission gate, when pivotal clinical trial protocols were often already fixed.
By pausing TCET for new candidates and launching RAPID, CMS is pivoting its medical device coverage strategy from retrospective post-market evidence remediation toward prospective pre-market trial coordination.
The notice pauses TCET for new candidates. It does not publish a separate processing rule for any manufacturer already in the TCET queue. Teams with a prior TCET candidacy should not assume RAPID enrollment, and they should not assume an automatic wind-down date that the August 11 notice does not state.
The Accelerated NCD Clock: Same-Day Proposed NCD vs. 60-Day Final NCD Goal
For medical device innovators that successfully navigate RAPID parallel review, the procedural notice outlines an unprecedented national coverage timeline:
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ RAPID PARALLEL REVIEW LIFECYCLE & MILESTONE CLOCK │
│ │
│ [IDE Presubmission] ────► [Parallel Trial Design] ────► [IDE Study Execution] │
│ • Sponsor enters TAP • CMS + FDA co-review • Medicare cohort enrollment │
│ • CMS joins presub • Endpoints aligned • Pre-specified outcome data │
│ │ │
│ ┌────────────────────────────────────────────────────────────────┘ │
│ ▼ │
│ [FDA Action Day (Day 0)] ─► [30-Day Comment Window] ─► [Final NCD Goal (~Day 60/90)] │
│ • FDA grants De Novo/PMA • Public comments on • Class II De Novo: ~60 Days │
│ • CMS posts Proposed NCD Proposed NCD • Class III PMA: ~90 Days │
│ • Tracking Sheet live • National Coverage Effective │
└──────────────────────────────────────────────────────────────────────────────────────────────────┘
Understanding the Same-Day Proposed NCD Mechanism
Under standard Medicare procedures, initiating a National Coverage Determination after FDA approval requires submitting a formal request package, undergoing a 30-day completeness review, publishing a tracking sheet, and waiting up to six months for a proposed decision, followed by an additional three to six months for a final NCD.
Under RAPID:
- Day of Market Authorization (Day 0): On the exact same day that FDA issues a De Novo grant order or PMA approval letter, CMS will publish a public tracking sheet and Proposed NCD establishing national Medicare coverage.
- Statutory 30-Day Comment Window: As mandated by Section 1862(l) of the Social Security Act, the public is afforded a 30-calendar-day comment period on the proposed coverage language.
- Target Final NCD Issuance: CMS establishes an operational goal of issuing the Final NCD within approximately 60 calendar days of authorization for Class II De Novo devices, and within 90 calendar days for Class III PMA devices.
Critical Analytical Distinction: Market access teams must not mistake this operational goal for an automatic entitlement. The 60-day timeline applies exclusively to technologies that have satisfied all RAPID presubmission milestones and generated robust Medicare-specific evidence during their IDE trials.
Why Abbott's Libre Duo De Novo Is Excluded from RAPID
The practical application of RAPID's eligibility filters is demonstrated by examining recent regulatory approvals across the medtech sector.
Case Study: Libre Duo 10 Day Continuous Glucose-Ketone Monitor
On August 25, 2026, the FDA granted De Novo classification to Abbott's Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged 2 years and older with diabetes. While Libre Duo was developed following a Breakthrough Device designation, it is entirely outside the RAPID coverage pathway:
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ LIBRE DUO DE NOVO VS. RAPID PATHWAY ELIGIBILITY AUDIT │
├───────────────────────┬───────────────────────────────────┬──────────────────────────────────────┤
│ Regulatory Element │ Libre Duo De Novo (August 25) │ RAPID Pathway Requirement │
├───────────────────────┼───────────────────────────────────┼──────────────────────────────────────┤
│ FDA Review Status │ MARKET-AUTHORIZED (De Novo Grant) │ MUST BE AT IDE PRESUBMISSION STAGE │
│ Breakthrough Status │ Designated Breakthrough Device │ Designated Breakthrough Device │
│ Medicare Payment Path │ Governed by DME MAC LCD L33822 │ Prospective National Coverage Determ.│
│ │ and Policy Article A52464 │ under SSA § 1862(a)(1)(A) │
│ RAPID Eligibility │ INELIGIBLE: Already authorized; │ Target: Unapproved devices planning │
│ │ past presubmission milestone │ upcoming IDE clinical trials │
└───────────────────────┴───────────────────────────────────┴──────────────────────────────────────┘
As analyzed in our dedicated breakdown of Libre Duo De Novo is not a Medicare CGM coverage decision, Medicare coverage for continuous glucose monitors is governed at the regional contractor level under Durable Medical Equipment Medicare Administrative Contractor (DME MAC) LCD L33822 and Policy Article A52464. Because Libre Duo is already FDA-authorized, Abbott cannot retroactively enter RAPID; its reimbursement path remains the LCD/HCPCS analysis on that page, not this NCD clock.
Coverage with Evidence Development (CED) in RAPID Decisions
A crucial consideration for medical device sponsors is whether completing RAPID guarantees unrestricted national coverage under Section 1862(a)(1)(A) or attaches Coverage with Evidence Development (CED) under Section 1862(a)(1)(E).
Aligning CED with FDA Post-Approval Studies (PAS)
In the August 2026 procedural notice and accompanying fact sheet, CMS explicitly notes that CED may still be required for higher-risk devices or technologies where significant evidentiary uncertainties remain regarding real-world effectiveness in elderly or multi-morbid Medicare subpopulations:
- Preventing Duplicative Registries: Under legacy CED policies, manufacturers often had to fund separate, redundant clinical registries for CMS after already agreeing to an FDA Post-Approval Study (PAS) or Section 522 post-market surveillance order.
- Unified Registry Architecture: Under RAPID, CMS intends to harmonize CED data collection requirements directly with FDA PAS protocols, allowing a single clinical registry or observational cohort to satisfy both regulatory bodies simultaneously.
- Finite CED Duration: CMS reiterates that CED is not intended to remain in place indefinitely, committing to structured evidentiary re-evaluations once post-market study milestones are met.
Impact on Existing PharmaDossier Device Analysis and Guidance
The establishment of the RAPID pathway directly updates key reference analyses across our medtech coverage portfolio:
- In our annual census of FDA device clearances by the numbers, sections detailing proposed TCET mechanisms will be updated to reflect the TCET pause and the elevation of RAPID as CMS's primary Breakthrough device coverage vehicle.
- In our analysis of commercial wearable diagnostics, see Libre Duo De Novo is not a Medicare CGM coverage decision for operational guidance on how DME MAC criteria diverge from national coverage pathways.
Frequently Asked Questions
Does RAPID automatically cover every FDA Breakthrough device the day it is authorized?
No. RAPID is not an automatic coverage mandate. It is a voluntary, prospective program open only to Breakthrough devices that enter at the IDE presubmission stage, align clinical trial protocols with CMS, and complete parallel review. For completers, CMS issues a Proposed NCD on the day of authorization, with a goal of finalizing national coverage within 60 to 90 days.
Can a manufacturer whose IDE study is already underway enroll in RAPID?
No. CMS explicitly states in the August 11, 2026 notice that devices beyond the IDE presubmission stage—including technologies whose IDE clinical studies are already underway or enrolling—are not appropriate for RAPID. Those manufacturers must pursue standard coverage mechanisms under 78 FR 48164 or local MAC LCDs.
Did CMS pause the TCET pathway?
Yes. Upon publication of the August 11, 2026 notice, CMS paused the Transitional Coverage for Emerging Technologies (TCET) pathway for new candidate submissions. The notice does not publish a separate processing rule for any manufacturer already in the TCET queue.
Are laboratory tests and other in vitro diagnostics (IVDs) eligible for RAPID?
No. The procedural notice specifically excludes IVDs and diagnostic laboratory tests from RAPID. CMS determined that most Breakthrough IVD coverage should remain with Medicare Administrative Contractors (MACs) through existing local pathways.
Sources
- Federal Register / Centers for Medicare & Medicaid Services: Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Procedural Notice with Comment Period. FR Doc. 2026-16368; 91 FR 51710–51718; File Code CMS-3487-NC; Docket CMS-2026-2674. Published August 11, 2026; comments close October 13, 2026. https://www.federalregister.gov/documents/2026/08/11/2026-16368/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway
- Centers for Medicare & Medicaid Services (CMS): Fact Sheet: Regulatory Alignment for Predictable and Immediate Device Coverage Pathway (CMS-3487-NC) Procedural Notice Inviting Comment. Published August 2026. https://www.cms.gov/newsroom/fact-sheets/regulatory-alignment-predictable-immediate-device-coverage-pathway-cms-3487-nc-procedural-notice
- U.S. Food and Drug Administration (FDA): CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices. Press Announcement. Published April 23, 2026. https://www.fda.gov/news-events/press-announcements/cms-and-fda-announce-rapid-coverage-pathway-accelerate-patient-access-life-changing-medical-devices
- Social Security Administration: Social Security Act Section 1862(a)(1)(A) & (a)(1)(E) – Exclusions from Coverage and Coverage with Evidence Development. 42 U.S.C. § 1395y. https://www.ssa.gov/OP_Home/ssact/title18/1862.htm
- Centers for Medicare & Medicaid Services (CMS): Revised Process for Making Medicare National Coverage Determinations. Notice (78 FR 48164). https://www.federalregister.gov/documents/2013/08/07/2013-19060/medicare-program-revised-process-for-making-medicare-national-coverage-determinations
- Centers for Medicare & Medicaid Services (CMS): Local Coverage Determination (LCD) L33822 – Glucose Monitors. DME MAC Jurisdiction. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822
